"The stock is up 179% YTD"? AND it's DOWN about 99.40% since it's IPO date in 2008. It's DOWN about 93% or so, since the present CEO took over in 2010 (despite him and Comella getting very large pay package increases in the 2013 10-K filing, with "bonuses", and the stock hitting it's all time low of 6/10ths of one cent in late 2013). (this is CEO number 4 or 5 in about as many years- Pinon, Leonhardt, Groth, Leonhardt again I think, and now Tomas)
"BIOHEART, INC. REPORTS SIGNIFICANT REVENUE INCREASES" blah, blah, blah. They also reported a LARGER OPERATIONAL LOSS for the same period, yr over yr. (see 10-K/10-Q filings under loss from operations). Kinda always leave that little "tid-bit" out of that PR. Their expenses more than doubled and far outpaced the "revenue" reported. See the SG&A line entry for expenses (marketing, general and administrative).
When your expenses and spending rise faster than any "revenues", it really doesn't matter what the "revenues" are. There are companies, with literally, $1 BILLION or more in "revenues" who went or are going BK or are teetering on insolvency and can't make a profit to save their lives. Sears being a prime example in today's world. Sears has $35 BA BILLION in "revenues" (and owns the K-Mart chain and store brand too) and is on life support. Nortel, the largest tech company and tel-com company in the history of Canada, BK. Kodak, an American icon brand and household name, with $16 BILLION or so in revenues at one time, BK and gone. Six Flags amusement parks filed BK. Avon, on life support. Look at what happened to Nokia. The list is long.
Despite those reported "significant revenue increases" and the PR all about it, the 10-Q showed they finished that Qtr as "normal", as in, nearly cash broke and cash poor stacked against large, short term debt and also very large long terms debt(s). Nothing changed in their "going concern" position because of those "significant revenues". They spent more than they took in, by far, and had enormous short term debts still. ($4 million or more in just accounts payable and accrued expenses, with about $200K cash left on the books)
A few hundred thousand in so called "revenues" is noise level money- especially in high technology bio-tech, where they are supposedly supposed to be conducting FDA level, phase II/III trials. It would not be unusual to need in the many $10's of MILLIONS of dollars, maybe as much as $100 MILLION or more and still be taking losses while running trials and seeking an FDA or Euro or similar legit regulatory body approval, for just one product.
